Time-dependent activation of MAPK/Erk1/2 and Akt/GSK3 cascades: modulation by agomelatine

BMC Neuroscience

Daniela Tardito²  Giorgio Racagni¹  Paolo Tornese²  Mariagrazia Pelizzari²  Giulia Treccani²  Alessandra Mallei²  Mara Seguini²  Laura Musazzi² 

[1] Istituto di Ricovero e Cura a Carattere Scientifico Centro S. Giovanni di Dio-Fatebenefratelli, Brescia, Italy;Laboratory of Neuropsychopharmacology and Functional Neurogenomics, Dipartimento di Scienze Farmacologiche e Biomolecolari and Center of Excellence on Neurodegenerative Diseases (CEND), Università degli Studi di Milano, Via Balzaretti 9, Milano 20133, Italy

关键词: Time-dependent regulation;    Neuroplasticity;    Intracellular signalling;    Agomelatine;    Antidepressant;   

Others  :  1090796
DOI  :  10.1186/s12868-014-0119-1

 received in 2014-08-08, accepted in 2014-10-09,  发布年份 2014

【 摘 要 】

Background

The novel antidepressant agomelatine, a melatonergic MT₁/MT₂ agonist combined with 5-HT_2c serotonin antagonist properties, showed antidepressant action in preclinical and clinical studies. There is a general agreement that the therapeutic action of antidepressants needs the activation of slow-onset adaptations in downstream signalling pathways finally regulating neuroplasticity. In the last several years, particular attention was given to cAMP-responsive element binding protein (CREB)-related pathways, since it was shown that chronic antidepressants increase CREB phosphorylation and transcriptional activity, through the activation of calcium/calmodulin-dependent (CaM) and mitogen activated protein kinase cascades (MAPK/Erk1/2).

Aim of this work was to analyse possible effects of chronic agomelatine on time-dependent changes of different intracellular signalling pathways in hippocampus and prefrontal/frontal cortex of male rats. To this end, measurements were performed 1 h or 16 h after the last agomelatine or vehicle injection.

Results

We have found that in naïve rats chronic agomelatine, contrary to traditional antidepressants, did not increase CREB phosphorylation, but modulates the time-dependent regulation of MAPK/Erk1/2 and Akt/glycogen synthase kinase-3 (GSK-3) pathways.

Conclusion

Our results suggest that the intracellular molecular mechanisms modulated by chronic agomelatine may be partly different from those of traditional antidepressants and involve the time-dependent regulation of MAPK/Erk1/2 and Akt/GSK-3 signalling pathways. This could exert a role in the antidepressant efficacy of the drug.

【 授权许可】

   
2014 Musazzi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Duman RS: Synaptic plasticity and mood disorders. Mol Psychiatry 2002, 7(Suppl 1):S29-S34.
• [2]Krishnan V, Nestler EJ: Linking molecules to mood: new insight into the biology of depression. Am J Psychiatry 2010, 167:1305-1320.
• [3]Racagni G, Popoli M: Cellular and molecular mechanisms in the long-term action of antidepressants. Dialogues Clin Neurosci 2010, 10:385-400.
• [4]Popoli M, Mori S, Brunello N, Perez J, Gennarelli M, Racagni G: Serine/threonine kinases as molecular targets of antidepressants: implications for pharmacological treatment and pathophysiology of affective disorders. Pharmacol Ther 2001, 89:149-170.
• [5]Blendy JA: The role of CREB in depression and antidepressant treatment. Biol Psychiatry 2006, 59:1144-1150.
• [6]Carlezon WA Jr, Duman RS, Nestler EJ: The many faces of CREB. Trends Neurosci 2005, 28:436-445.
• [7]Tardito D, Perez J, Tiraboschi E, Musazzi L, Racagni G, Popoli M: Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol Rev 2006, 58:115-134.
• [8]McClung CA, Nestler EJ: Neuroplasticity mediated by altered gene expression. Neuropsychopharmacol 2008, 33:3-17.
• [9]Pittenger C, Duman RS: Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacol 2008, 33:88-109.
• [10]Tiraboschi E, Tardito D, Kasahara J, Moraschi S, Pruneri P, Gennarelli M, Racagni G, Popoli M: Selective phosphorylation of nuclear CREB by fluoxetine is linked to activation of CaM kinase IV and MAP kinase cascades. Neuropsychopharmacol 2004, 29:1831-1840.
• [11]Tardito D, Musazzi L, Tiraboschi E, Mallei A, Racagni G, Popoli M: Early induction of CREB activation and CREB-regulating signalling by antidepressants. Int J Neuropsychopharmacol 2009, 12:1367-1381.
• [12]Alboni S, Benatti C, Capone G, Corsini D, Caggia F, Tascedda F, Mendlewicz J, Brunello N: Time-dependent effects of escitalopram on brain derived neurotrophic factor (BDNF) and neuroplasticity related targets in the central nervous system of rats. Eur J Pharmacol 2010, 643:180-187.
• [13]Beaulieu JM, Gainetdinov RR, Caron MG: Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 2009, 49:327-347.
• [14]Li X, Jope RS: Is glycogen synthase kinase-3 a central modulator in mood regulation? Neuropsychopharmacol 2010, 35:2143-2154.
• [15]Machado-Vieira R, Salvadore G, DiazGranados N, Ibrahim L, Latov D, Wheeler-Castillo C, Baumann J, Henter ID, Zarate CA Jr: New therapeutic targets for mood disorders. ScientificWorldJournal 2010, 10:713-726.
• [16]Grimes CA, Jope RS: The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 2001, 65:391-426.
• [17]Beaulieu JM: A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. J Psychiatry Neurosci 2012, 37:7-16.
• [18]Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA: Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 2004, 36:131-137.
• [19]Li X, Zhu W, Roh MS, Friedman AB, Rosborough K, Jope RS: In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacol 2004, 29:1426-1431.
• [20]Beaulieu JM, Zhang X, Rodriguiz RM, Sotnikova TD, Cools MJ, Wetsel WC, Gainetdinov RR, Caron MG: Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci U S A 2008, 105:1333-1338.
• [21]Polter AM, Yang S, Jope RS, Li X: Functional significance of glycogen synthase kinase-3 regulation by serotonin. Cell Signal 2012, 24:265-271.
• [22]Gould TD, Einat H, Bhat R, Manji HK: AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 2004, 7:387-390.
• [23]Rosa AO, Kaster MP, Binfaré RW, Morales S, Martín-Aparicio E, Navarro-Rico ML, Martinez A, Medina M, García AG, López MG, Rodrigues AL: Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1549-1556.
• [24]Beurel E, Song L, Jope RS: Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry 2011, 16:1068-1070.
• [25]De Bodinat C, Guardiola-Lemaitre B, Mocaër E, Renard P, Muñoz C, Millan MJ: Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 2010, 8:628-642.
• [26]Popoli M: Agomelatine: innovative pharmacological approach in depression. CNS Drugs 2009, 23:27-34.
• [27]Racagni G, Riva MA, Molteni R, Musazzi L, Calabrese F, Popoli M, Tardito D: Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors. World J Biol Psychiatry 2011, 12:574-587.
• [28]Smeraldi E, Delmonte D: Agomelatine in depression. Expert Opin Drug Saf 2013, 12:873-880.
• [29]Guardiola-Lemaitre B, De Bodinat C, Delagrange P, Millan MJ, Munoz C, Mocaër E: Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties. Br J Pharmacol 2014, 171:3604-3619.
• [30]Morley-Fletcher S, Mairesse J, Soumier A, Banasr M, Fagioli F, Gabriel C, Mocaer E, Daszuta A, McEwen B, Nicoletti F, Maccari S: Chronic agomelatine treatment corrects behavioral, cellular, and biochemical abnormalities induced by prenatal stress in rats. Psychopharmacology (Berl) 2011, 217:301-313.
• [31]Soumier A, Banasr M, Lortet S, Masmejean F, Bernard N, Kerkerian-Le-Goff L, Martinez A, Medina M, García AG, López MG, Rodrigues AL: Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacol 2009, 34:2390-2403.
• [32]Païzanis E, Renoir T, Lelievre V, Saurini F, Melfort M, Gabriel C, Barden N, Mocaer E, Hamon M, Lanfumey L: Behavioural and neuroplastic effects of the new-generation antidepressant agomelatine compared to fluoxetine in glucocorticoid receptor-impaired mice. Int J Neuropsychopharmacol 2010, 13:759-774.
• [33]Molteni R, Calabrese F, Pisoni S, Gabriel C, Mocaer E, Racagni G, Riva MA: Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration. World J Biol Psychiatry 2010, 11:148-153.
• [34]Calabrese F, Molteni R, Gabriel C, Mocaer E, Racagni G, Riva MA: Modulation of neuroplastic molecules in selected brain regions after chronic administration of the novel antidepressant agomelatine. Psychopharmacology (Berl) 2011, 215:267-275.
• [35]Ladurelle N, Gabriel C, Viggiano A, Mocaër E, Baulieu EE, Bianchi M: Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC. Psychopharmacology (Berl) 2012, 221:493-509.
• [36]Cao R, Anderson FE, Jung YJ, Dziema H, Obrietan K: Circadian regulation of mammalian target of rapamycin signaling in the mouse suprachiasmatic nucleus. Neuroscience 2011, 181:79-88.
• [37]Eckel-Mahan KL, Phan T, Han S, Wang H, Chan GC, Scheiner ZS, Storm DR: Circadian oscillation of hippocampal MAPK activity and cAMP: implications for memory persistence. Nat Neurosci 2008, 11:1074-1082.
• [38]Phan TX, Chan GC, Sindreu CB, Eckel-Mahan KL, Storm DR: The diurnal oscillation of MAP (mitogen-activated protein) kinase and adenylyl cyclase activities in the hippocampus depends on the suprachiasmatic nucleus. J Neurosci 2011, 31:10640-10647. Erratum in: J Neurosci 2011, 31:11744
• [39]Zheng X, Sehgal A: AKT and TOR signaling set the pace of the circadian pacemaker. Curr Biol 2010, 20:1203-208.
• [40]Kaladchibachi SA, Doble B, Anthopoulos N, Woodgett JR, Manoukian AS: Glycogen synthase kinase 3, circadian rhythms, and bipolar disorder: a molecular link in the therapeutic action of lithium. J Circadian Rhythms 2007, 5:3. BioMed Central Full Text
• [41]Roskoski R Jr: ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res 2012, 66:105-143.
• [42]Zehorai E, Yao Z, Plotnikov A, Seger R: The subcellular localization of MEK and ERK: a novel nuclear translocation signal (NTS) paves a way to the nucleus. Mol Cell Endocrinol 2010, 314:213-220.
• [43]Barbiero VS, Giambelli R, Musazzi L, Tiraboschi E, Tardito D, Perez J, Drago F, Racagni G, Popoli M: Chronic antidepressants induce redistribution and differential activation of alphaCaM kinase II between presynaptic compartments. Neuropsychopharmacol 2007, 32:2511-2519.
• [44]Ryan B, Musazzi L, Mallei A, Tardito D, Gruber SH, El Khoury A, Anwyl R, Racagni G, Mathé AA, Rowan MJ, Popoli M: Remodelling by early-life stress of NMDA receptor-dependent synaptic plasticity in a gene-environment rat model of depression. Int J Neuropsychopharmacol 2009, 12:553-559.